FMP
Enlivex Therapeutics Ltd.
ENLV
NASDAQ
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
1.24 USD
0.06 (4.84%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Oren Hershkovitz Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.enlivex.comexchange
NASDAQ
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
CIK
0001596812
ISIN
IL0011319527
CUSIP
M4130Y106
Address
14 Einstein Street
Phone
972 8 662 3301
Country
IL
Employee
71
IPO Date
Jul 31, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ENLV Financial Summary
CIK
0001596812
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
M4130Y106
ISIN
IL0011319527
Country
IL
Price
1.24
Beta
1.1
Volume Avg.
236.74k
Market Cap
27.27M
Shares
-
52-Week
0.81-4.59
DCF
-0.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.27
P/B
-
Website
https://www.enlivex.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ENLV News
It looks like there's no news available.
